Renalytix Secures KidneyIntelX Coverage with BCBSTX and PCHP, Boosting Reach in Texas

Renalytix expands insurance coverage of KidneyIntelX™ in the state of Texas having executed a contract with BlueCross and BlueShield of Texas (BCBSTX), the largest statewide health care plan serving 7 million

Renalytix expands insurance coverage of KidneyIntelX™ in the state of Texas having executed a contract with BlueCross and BlueShield of Texas (BCBSTX), the largest statewide health care plan serving 7 million members in all 254 Texas counties. BCBSTX works with more than 140,000 physicians and healthcare practitioners, and 520 hospitals. In addition, Renalytix has executed an agreement for insurance coverage of KidneyIntelX with Parkland Community Health Plan (PCHP), a Dallas-based insurance plan with over 300,000 covered lives and service in seven counties.

The BCBSTX agreement complements coverage already secured with several other Blue Cross Blue Shield plans including Wellmark Blue Cross Blue Shield in Iowa and South Dakota (estimated 2.1 million covered lives), BlueCross BlueShield of Illinois (estimated 8.1 million covered lives) and CareFirst BlueCross BlueShield (estimated 3.4 million covered lives). Renalytix believes achieving payer coverage with these large state-wide plans is a critical component to bringing the benefits of KidneyIntelX prognostic technology to large populations of adults with type 2 diabetes and early stage kidney disease.

Total
0
Shares
Related Posts
Read More

DMT’s Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and Traumati

AGNPF